In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid

Japanese Journal of Infectious Diseases

Volumn 60, Issue 4, 2007, Pages 227-229

  Kacmaz, Birgul ^a   Sultan, Nedim ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMOXICILLIN PLUS CLAVULANIC ACID; SULTAMICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; ESCHERICHIA COLI; IN VITRO STUDY; INTERMETHOD COMPARISON; KLEBSIELLA; NONHUMAN;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; AMPICILLIN; COLONY COUNT, MICROBIAL; DIFFUSION CHAMBERS, CULTURE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA; SULBACTAM;

EID: 34548445105     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Paterson, D.L. and Bonomo, R.A. (2005): Extended-spectrum betalactamases: a clinical update. Clin. Microbiol. Rev., 18, 657-686.
2. National Committee for Clinical Laboratory Standards (2004): Performance standards for antimicrobial susceptibility testing. 5th ed. Approved Standard M100-S14(M7-A6). Wayne, Pa.
3. O'Shaughnessy, E.M., Fahle, G.A. and Witebsky, F.G. (1997): Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli. J. Clin. Microbiol., 35, 1902-1903.
4. Babic, M., Hujer, A.A. and Bonomo, R.A. (2006): What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist. Updates, 9, 142-156.
5. Weldhagen, G.F. (2004): Integrons and beta-lactamases- a novel perspective on resistance. Int. J. Antimicrob. Agents, 23, 556-562.
6. Shah, A.A., Hasan, F., Ahmed, S., et al. (2004): Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-sectrum β4-lactamases. Res. Microbiol., 155, 409-421.
7. Helfand, M.S. and Bonomo, R.A. (2003): β-lactamases: a survey of protein diversity. Curr. Drug Targets Infect. Disord., 3, 9-23.
8. Livermore, D.M. (1993): Determinants of the activity of beta-lactamase inhibitor combinations. J. Antimicrob. Chemother., 31, 9-21.
9. Reguera, J.A., Baquero, F., Perez-Diaz, J.C., et al. (1991): Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. J. Antimicrob. Chemother., 27, 5696-575.
10. Vanjak, D., Mulleys, C., Picard, B., et al. (1995): Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. Eur. J. Clin. Microbiol. Infect. Dis., 14, 972-978.
11. Oliver, A., Perez-Vazquez, M., Martinez Ferrer, M., et al,. (1999): Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes. Antimicrob. Agents Chemother., 43, 862-867.
12. Jones, R.N. and Barry, A.L. (1987): Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. J. Clin. Microbiol., 25, 1920-1925.
13. Stapleton, P., Wu, P.J., King, A., et al. (1995): Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother., 39, 2478-2483.